+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nonsteroidal MRAs Market - Global Forecast 2025-2030- Product Image
Nonsteroidal MRAs Market - Global Forecast 2025-2030- Product Image
Sale

Nonsteroidal MRAs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6126736
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Nonsteroidal mineralocorticoid receptor antagonists (MRAs) are redefining cardiorenal and hypertensive care, driven by advancements in selective receptor modulation and novel clinical strategies. These agents are supporting strategic adoption across chronic kidney disease, heart failure, and hypertension through differentiated safety profiles and increased real-world evidence.

Market Snapshot: Nonsteroidal Mineralocorticoid Receptor Antagonists

The global market for nonsteroidal MRAs is experiencing robust growth, supported by innovation in drug design, positive clinical trial outcomes, and expedited regulatory approvals. Pharmaceutical manufacturers and technology providers are increasingly collaborating to drive targeted product development and move candidates rapidly through pivotal studies. The adoption of these advanced therapies is influenced by their capacity to address long-standing limitations of steroidal alternatives while meeting evolving regulatory and payer requirements. Expansion is further supported by the integration of artificial intelligence and digital health technologies, providing deeper insights into product performance, patient monitoring, and safety modeling.

Scope & Segmentation

This report delivers a comprehensive overview of the nonsteroidal MRA market, outlining key segments, regional dynamics, and technology trends.

  • Therapeutic Indications: Chronic kidney disease (including diabetic and non-diabetic subtypes), heart failure (with preserved or reduced ejection fraction), and hypertension (primary, and resistant forms).
  • Product Types: Established agents such as finerenone, alongside emerging nonsteroidal MRAs like esaxerenone.
  • Distribution Channels: Hospital pharmacy, retail pharmacy, and online pharmacy, each addressing distinct procurement and patient adherence requirements.
  • End Users: Home care settings, hospitals, and specialty clinics, reflecting diverse care pathways and patient engagement models.
  • Route of Administration: Oral dosage forms including capsules and tablets, emphasizing formulation design and stability.
  • Regional Coverage: Americas (United States—including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—plus Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (spanning United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (featuring China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Players: Bayer Aktiengesellschaft, Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, AstraZeneca PLC, NGM Biopharmaceuticals, Inc., and Pfizer Inc.

Key Takeaways for Senior Decision-Makers

  • Selective receptor targeting in nonsteroidal MRAs is driving broad adoption due to reduced endocrine and electrolyte-related safety concerns.
  • Digital health integration—such as remote monitoring and AI safety modeling—enhances data generation, facilitating trust among providers and payers.
  • Real-world evidence complements clinical trial data, underpinning successful formulary discussions and accelerating reimbursement processes.
  • Strategic collaborations, including joint ventures and licensing partnerships, enable resource optimization and efficient clinical advancement for both established companies and innovative biotech firms.
  • Regional differences in regulatory frameworks, reimbursement systems, and healthcare infrastructures require tailored market access and adoption strategies.
  • Operational adaptability in supply chain management and distribution ensures sustained availability, especially given external influences like tariff changes.

Tariff Impact on Accessibility and Development

Upcoming United States tariff adjustments in 2025 are set to increase sourcing costs for specialized raw materials crucial to nonsteroidal MRA synthesis. Industry leaders are responding by diversifying supplier bases, enhancing domestic production capabilities, and renegotiating distribution contracts to control logistics expenses. Contract development and manufacturing organizations are reassessing capacities, with downstream partners adopting cost-containment strategies such as volume-based agreements and route optimization. Regulatory and legal teams are proactively engaging with customs advisors to ensure seamless compliance and mitigate disruption. These operational shifts are crucial for maintaining therapy accessibility and supporting continued development momentum.

Methodology & Data Sources

This analysis utilizes a multi-stage research process, beginning with exhaustive review of secondary sources—including peer-reviewed journals, regulatory reports, patent filings, and proprietary databases. Key primary insights were gathered from extensive interviews with clinicians, policymakers, payers, and senior pharmaceutical executives. Data triangulation and advanced statistical modeling validate quantitative and qualitative findings, while expert panel review ensures precision and reliability.

Why This Report Matters

  • Informed decision-making based on a holistic overview of clinical, regulatory, and operational trends for nonsteroidal MRAs.
  • Actionable segmentation and regional strategy insights support targeted investments and optimized resource allocation.
  • Guidance for navigating evolving partnerships, technology integration, and external policy impacts to drive sustained market leadership.

Conclusion

Nonsteroidal mineralocorticoid receptor antagonists are positioned as key disruptors in the cardiorenal and hypertension treatment landscape. This report equips leaders with essential insights to accelerate innovation, secure market access, and achieve long-term competitive advantage.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging clinical trial results demonstrating improved safety profiles of nonsteroidal MRAs in high-risk heart failure populations
5.2. Increasing adoption of biomarker-driven patient stratification strategies to optimize nonsteroidal MRA therapy outcomes
5.3. Growing partnerships between pharmaceutical companies and academic institutions to accelerate nonsteroidal MRA research and development
5.4. Shifting competitive landscape with biosimilar entrants and novel nonsteroidal antagonists challenging market incumbents
5.5. Impact of evolving regulatory guidelines on nonsteroidal MRA labeling, reimbursement and market access dynamics
5.6. Rising investment in combination therapy studies evaluating nonsteroidal MRAs alongside SGLT2 inhibitors and ARNI treatments
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Nonsteroidal MRAs Market, by Therapeutic Indication
8.1. Introduction
8.2. Chronic Kidney Disease
8.2.1. Diabetic Chronic Kidney Disease
8.2.2. Non-Diabetic Chronic Kidney Disease
8.3. Heart Failure
8.3.1. Heart Failure With Preserved Ejection Fraction
8.3.2. Heart Failure With Reduced Ejection Fraction
8.4. Hypertension
8.4.1. Primary Hypertension
8.4.2. Resistant Hypertension
9. Nonsteroidal MRAs Market, by Product Type
9.1. Introduction
9.2. Emerging Nonsteroidal MRAs
9.2.1. Esaxerenone
9.3. Finerenone
10. Nonsteroidal MRAs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Nonsteroidal MRAs Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Nonsteroidal MRAs Market, by Route of Administration
12.1. Introduction
12.2. Oral
12.2.1. Capsule
12.2.2. Tablet
13. Americas Nonsteroidal MRAs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Nonsteroidal MRAs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Nonsteroidal MRAs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bayer Aktiengesellschaft
16.3.2. Daiichi Sankyo Company, Limited
16.3.3. Mitsubishi Tanabe Pharma Corporation
16.3.4. AstraZeneca PLC
16.3.5. NGM Biopharmaceuticals, Inc.
16.3.6. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NONSTEROIDAL MRAS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NONSTEROIDAL MRAS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NONSTEROIDAL MRAS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. NONSTEROIDAL MRAS MARKET: RESEARCHAI
FIGURE 26. NONSTEROIDAL MRAS MARKET: RESEARCHSTATISTICS
FIGURE 27. NONSTEROIDAL MRAS MARKET: RESEARCHCONTACTS
FIGURE 28. NONSTEROIDAL MRAS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NONSTEROIDAL MRAS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY DIABETIC CHRONIC KIDNEY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY DIABETIC CHRONIC KIDNEY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY NON-DIABETIC CHRONIC KIDNEY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY NON-DIABETIC CHRONIC KIDNEY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE WITH PRESERVED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE WITH PRESERVED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE WITH REDUCED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE WITH REDUCED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY RESISTANT HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY RESISTANT HYPERTENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ESAXERENONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ESAXERENONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY FINERENONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY FINERENONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES NONSTEROIDAL MRAS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 115. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 116. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 117. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 118. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 119. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 120. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 121. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 122. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 123. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 125. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 126. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 127. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 134. CANADA NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 135. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 136. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 137. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 140. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 141. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 142. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 143. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 146. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 147. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 154. MEXICO NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA NONSTEROIDAL MRAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 237. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 238. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 239. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 240. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 241. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 242. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 243. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 244. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 245. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 248. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 249. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 256. GERMANY NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 257. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 258. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 259. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 260. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 261. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 262. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 263. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 264. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 265. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 266. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 267. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 268. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 269. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 276. FRANCE NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 297. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 298. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 299. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 300. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 301. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 302. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 303. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 304. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 305. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 306. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 307. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 308. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 309. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 316. ITALY NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 317. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 318. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 319. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2018-2024 (USD MILLION)
TABLE 320. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE, 2025-2030 (USD MILLION)
TABLE 321. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2018-2024 (USD MILLION)
TABLE 322. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY HEART FAILURE, 2025-2030 (USD MILLION)
TABLE 323. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2018-2024 (USD MILLION)
TABLE 324. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY HYPERTENSION, 2025-2030 (USD MILLION)
TABLE 325. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 326. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 327. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2018-2024 (USD MILLION)
TABLE 328. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY EMERGING NONSTEROIDAL MRAS, 2025-2030 (USD MILLION)
TABLE 329. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 334. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 335. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 336. SPAIN NONSTEROIDAL MRAS MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Nonsteroidal MRAs market report include:
  • Bayer Aktiengesellschaft
  • Daiichi Sankyo Company, Limited
  • Mitsubishi Tanabe Pharma Corporation
  • AstraZeneca PLC
  • NGM Biopharmaceuticals, Inc.
  • Pfizer Inc.

Related Reports

Steroidal MRAs Market - Global Forecast 2025-2030 - Product Image

Steroidal MRAs Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Intracerebral Hemorrhage Market - Product Image

Intracerebral Hemorrhage Market

  • Report
  • 250 Pages
  • Global
From
Diabetic Kidney Diseases - Global Strategic Business Report - Product Image

Diabetic Kidney Diseases - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Congestive Heart Failure Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Congestive Heart Failure Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 137 Pages
  • Global
From
Cerebral Angiography - Global Strategic Business Report - Product Image

Cerebral Angiography - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.